Target intelligence / Profile preview

Expanded CUG repeat RNA in Dystrophia Myotonica Protein Kinase (DMPK) mRNA (CUGexp DMPK mRNA)

Target
CUGexp DMPK mRNA
Molecular classification
RNA, Toxic RNA gain-of-function, Other
01

Overview

The pathogenic expanded CUG repeat hairpin structure in the 3' untranslated region (UTR) of the Dystrophia Myotonica Protein Kinase (DMPK) mRNA is the primary molecular driver of Myotonic Dystrophy Type 1 (DM1) [1]. In affected individuals, the CTG repeat sequence in the DMPK gene expands significantly, often reaching hundreds or thousands of repeats, which are then transcribed into RNA that forms stable, double-stranded hairpin structures [2]. These expanded CUG repeats aggregate into nuclear foci and exert a toxic gain-of-function effect by sequestering essential RNA-binding proteins, most notably the Muscleblind-like (MBNL) family [3]. This sequestration leads to the stabilization of CELF1 and subsequent widespread mis-splicing of various pre-mRNAs, resulting in the multisystemic symptoms of DM1 such as myotonia and muscle wasting [1,2]. Therapeutic strategies targeting this structure primarily involve the use of antisense oligonucleotides (ASOs) or siRNAs to induce the degradation of the toxic transcript [4]. Additionally, research is ongoing into small molecules and steric-blocking oligonucleotides designed to displace sequestered MBNL proteins and restore normal cellular splicing patterns [5].

Other names
Toxic CUG repeatsDMPK 3' UTR CUG expansionCUGexp RNAMyotonic dystrophy type 1 RNA
02

Mechanism of action

RNase H-mediated degradation of expanded CUG repeat mRNA, RNA interference (RNAi) mediated cleavage of DMPK transcripts, and steric blocking of CUG repeats to prevent sequestration of RNA-binding proteins like MBNL1.

03

Biological functions

RNA processingSplicing regulationProtein sequestrationOther
04

Disease associations

Myotonic dystrophy type 1Other
05

Safety considerations

Potential for off-target knockdown of wild-type DMPK mRNAToxicity associated with antibody-oligonucleotide conjugate (AOC) delivery systemsImmune response to synthetic oligonucleotidesThrombocytopenia or renal toxicity common to antisense therapies
06

Interacting drugs

AOC 1001 (Delpacitug braxosotug)

3 more in the full profile.

07

Biomarkers

DMPK mRNA levels in muscle biopsyMBNL1 nuclear foci countCLCN1 exon 7a inclusion ratioINSR exon 11 exclusion ratioBIN1 exon 11 inclusion ratio

Beyond the preview

Go deeper on Expanded CUG repeat RNA in Dystrophia Myotonica Protein Kinase (DMPK) mRNA (CUGexp DMPK mRNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Expanded CUG repeat RNA in Dystrophia Myotonica Protein Kinase (DMPK) mRNA (CUGexp DMPK mRNA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call